Search Technologies

Researchers at the National Cancer Institute (NCI) developed novel molecular nanotags for single biological nanoparticle detection, resolution, and sorting, by flow cytometry. The National Cancer Institute (NCI) seeks licensing and/or co-development research collaborations to further advance this technology with extremely broad biomedical, biodefense, industrial, environmental, and other applications.

This technology is a method of inhibiting or delaying gene silencing through specific transgene constructs that would be used for generating gene therapy vectors.

The National Cancer Institute is seeking parties interested in collaborative research to co-develop or license the in vitro and in vivo removal of targets using light energy.

A human antibody that could be used safely in vitro and in vivo for the detection of CH2 (Fc and IgG as well is available of out-licensing from the National Cancer Institute.

The National Cancer Institute (NCI) seeks non-exclusive licensees for an ovarian cancer cell line, A2780, and its cisplatin- and/or adriamycin-resistant derivatives, A2780CIS and A2780ADR. These cell lines are excellent research tools to study ovarian cancer with a focus on drug resistance.

The National Cancer Institute seeks parties interested in co-development of safe and effective TEM5 agonists and/or antagonists that modulate WNT signaling.